Ocular Therapeutix Inc.

NASDAQ: OCUL · Real-Time Price · USD
12.44
-0.21 (-1.66%)
At close: Aug 15, 2025, 2:33 PM
-1.66%
Bid 12.43
Market Cap 2.16B
Revenue (ttm) 56.6M
Net Income (ttm) -216.75M
EPS (ttm) -1.26
PE Ratio (ttm) -9.87
Forward PE -8.2
Analyst Buy
Ask 12.44
Volume 963,366
Avg. Volume (20D) 2,358,935
Open 12.67
Previous Close 12.65
Day's Range 12.39 - 12.68
52-Week Range 5.79 - 12.91
Beta 1.49

About OCUL

undefined

Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol OCUL
Website n/a
Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for OCUL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Ocular Therapeutix has released their quartely earnings on Aug 5, 2025:
  • Revenue of $13.46M exceeds estimates by $166.23K, with -18.14% YoY decline.
  • EPS of -0.39 misses estimates by -0.04, with -50.00% YoY decline.
  • Next Earnings Release

    Ocular Therapeutix Inc. is scheduled to release its earnings on Nov 13, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 week ago
    -2.83%
    Ocular Therapeutix shares are trading lower after ... Unlock content with Pro Subscription
    2 months ago
    +13.69%
    Ocular Therapeutix shares are trading higher after the company announced that enrollment in the SOL-R registrational trial of its product candidate AXPAXLI in wet age-related macular degeneration will close this week.